Abstract
Background -In some carcinomas inactivation of the tumour suppressor gene product p53, either by point mutation or indirectly by the human papillomavirus (HPV), has been suggested as two alternative routes to malignant transformation. To test this hypothesis in lung tumours, 43 lung carcinomas were analysed by in situ hybridisation and polymerase chain reaction (PCR) for the presence of HPV DNA, and the results were compared with p53 protein immunohistochemical analysis. Methods -The presence of HPV DNA in lung carcinoma was detected by nucleic acid in situ hybridisation for HPV types 6, 11, 16, 18, 31 , and 33 using nonradioactively labelled DNA probes. Polymerase chain reaction (PCR) analysis was performed on all cases showing positive HPV DNA labelling by in situ hybridisation and in an additional 13 negative cases. Abnormal nuclear accumulation of the p53 protein was revealed by immunohistochemistry using the avidin-biotin-peroxidase complex method and a CM-1 polyclonal anti-human p53 antibody and a monoclonal mutationspecific Pab 240 p53 antibody. Results -HPV DNA was found by in situ hybridisation in 13 lung carcinomas (30%/6). In all these cases subtype-specific HPV DNA could also be detected by PCR. Abnormal p53 protein accumulation was seen in 21 of the 43 carcinomas (49%), of which 18 were HPV negative. Twelve (57%) of the CM-1 positive cases were also positive for the mutation-specific antibody Pab 240. There was an obvious inverse relationship between the presence of papilloma viral DNA and abnormal p53 protein accumulation.
Conclusions -p53 plays an important part in the development of lung carcinomas and, in some cases, HPV may contribute to it by binding and inactivating the p53 protein.
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p53 is a tumour suppressor gene, mutations of which have been found in a wide variety of malignant tumours.' 2 The p53 gene encodes a 53 kDa phosphoprotein which participates in the control of cell proliferation.3 4 Moreover, the p53 protein has been found to harbour transcription factor-like properties5 and it can also induce apoptosis.6 In cultured fibroblasts DNA-damaging ultraviolet irradiation leads to an increase in the level of p53.7 This has also been shown in human keratinocytes in vivo.'
On the basis of these properties, it has been suggested that the physiological function of p53 may be to act as a "guardian" of the genome.9 Since p53 is able to stall the cell cycle at Gl, p53 allows more time for DNA repairing enzymes to act in the event of DNA damage. In case of a failure in repair, p53 may trigger apoptosis of the damaged cells. If p53 fails in its functions, the DNA damage is preserved and transferred to the next cell generations.'
There are two major mechanisms behind p53 dysfunction. The first is a p53 gene mutation. This leads either to a cessation of the production of the p53 protein, or to synthesis of a mutated p53 protein which lacks the physiological properties of the wild type p53 protein but is more stable and consequently has a longer half life.'°" The accumulation of such a mutated dysfunctional protein can be detected immunohistochemically in the affected cells in contrast to the wild type protein which has such a short half life that it usually cannot be detected by -immunohistochemistry. " 13 Another mechanism of p53 dysfunction results from the capability of some viral and non-viral proteins to bind and inactivate the wild type p53 protein. ' The full case histories were re-evaluated from the medical records of the patients.
IN SITU HYBRIDISATION FOR HPV
Nucleic acid in situ hybridisation for the HPV types 6, 11, 16, 18, 31, and 33 was performed using non-radioactively labelled DNA probes and a commercially available hybridisation kit (Biohit, Helsinki, Finland) following the manufacturer's instructions. The deparaffinised and rehydrated 3-5 gm sections were first digested with proteinase K (final concentration 500 ,g/ml) at 37°C for 15 minutes, rinsed with phosphate buffered saline (PBS), and dehydrated. Hybridisation probes (20-40 tl/ section) were applied on the slides and the DNA was denatured at 93°C. The sections were hybridised in a humidified chamber at 50°C overnight. After hybridisation the sections were washed with sodium chloride/ sodium citrate (1 x SSC) (2 x 5 minutes at 60°C and 1 x 5 minutes at room temperature). Thereafter, gl of the detection reagent (alkaline phosphatase conjugated to streptavidin) was applied to the sections (20 minutes at 37°C) which were washed with Tris-buffered saline (TBS) (3 x 3 minutes). The slides were then incubated for 45 minutes at 370C in the substrate solution (600 gl nitroblue tetrazolium in dimethyl formamide and 600 ,l 5-bromo-4-chloro-3-indolylphosphate in dimethyl formamide) in 200 ml TBS, whereafter the slides were washed in distilled water, counterstained with Carbo-Fucsin (four minutes at room temperature), rinsed briefly in absolute ethanol and xylene, and mounted with Eukitt (Kindler, Freiburg, Germany).
As a positive control we used slides with acetone-fixed CaSki cells containing HPV 16 DNA (approximately 500 copies/cell) included in the kit and cervical samples shown to be positive for each of the HPV subtypes tested.23 Biotinylated pBR322 DNA, which was also included in the kit, was used as a negative control probe.
POLYMERASE CHAIN REACTION FOR HPV
Five to 10 sections, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The significance of the associations was determined using Fisher's exact probability test.
Results

IN SITU HYBRIDISATION
The results are summarised in table 2. Thirteen carcinomas (30%) were positive for HPV DNA by in situ hybridisation (table 2; fig  1) , nine of which were squamous cell carcinomas and four adenocarcinomas. Multiple HPV subtypes were detected in 11 tumours without any clustering of any particular subtype. In all cases HPV DNA was found in both the nuclear and the cytoplasmic compartments, and in most of the cases more than 40% of the neoplastic cells showed labelling for HPV DNA ( PCR by 0-globin primers gave a positive result in every case, indicating successful amplification of the genomic DNA in the samples and excluding false negative results. The amplification of sterile water gave consistently negative results, evidence against contamination of DNA during the procedure.
P53 IMMUNOHISTOCHEMISTRY AND ITS
ASSOCIATIONS
Twenty one of the 43 tumours (49%) showed positive staining for the p53 protein with the CM-1 antibody (fig 3) , of which 16 were squamous cell carcinomas, four adenocarcinomas, and one a small cell carcinoma, representing 55%, 33%, and 33%, respectively, of the tumours in the different histological categories. Eleven of the 13 HPV positive carcinomas (85%) were p53 negative as assessed by in situ hybridisation and confirmed by PCR. Thus, there was a significant inverse relationship between the presence of HPV DNA and immunohistochemically detectable abnormal accumulation of the p53 protein in the lung carcinomas (p < 0.05; table 3). All cases showing positivity for the Pab 240 antibody were also CM-1 positive. Pab 240 positivity was found in 12 cases, thus 57% of the CM-1 positive tumours were Pab 240 positive. There was a statistically significant association between CM-1 positivity and Pab 240 positivity (p < 0.05).
No positive staining was seen in nonneoplastic cells in any of the sections examined with either antibody.
Neither the presence of HPV DNA nor p53 positivity was associated with tumour size, the presence of lymph node metastases, or the prognosis determined as the patient's progression-free survival (data not shown).
Discussion
In this study a statistically significant inverse relationship was found between the presence of HPV DNA and abnormal accumulation of p53 protein, which indicates that there is a non-random concentration of HPV positive cases in tumours with no p53 protein detectable by immunohistochemistry. The accumulation of HPV DNA positivity in p53 negative tumours suggests that HPV infection gives this group of tumours a selective growth advantage. In previous studies it has been shown that the E6 protein encoded by the HPV virus is able to bind to wild type (normal) p53 protein.14 This binding leads to a rapid degradation of the p53 protein. Part of the transforming capacity of the HPV virus resides in this capacity to degrade wild type 53, since p53 takes part in the control of cell proliferation and repair of DNA damage. The presence of HPV infection may thus lead to a functional inactivation of p53 protein in the absence of a true p53 mutation. Even though we could not measure the half life and concentration of the wild type p53 protein in our samples, the presence of HPV DNA in these cases indirectly suggests that such an inactivation of the protein is taking place. Thus, the most likely explanation for the inverse relationship between p53 immunohistochemistry and HPV DNA findings is that, in cases where there is a p53 gene mutation, the mutation itself, by functionally inactivating the p53 protein, leads to a putative neoplastic transformation of the tumour cells. In the case of an HPV infection the production of the E6 protein leads to a rapid degradation of the p53 protein so that it cannot function normally, and this may then lead to a neoplastic transformation.
HPV DNA was detected in 13 of our 43 cases of lung carcinoma by in situ hybridisation, and in all 13 cases the results could be confirmed by PCR for most HPV subtypes. Some cases, however, remained unconfirmed (table 2) . Such cases are possibly due to a cross reaction between probes of different HPV subtypes in in situ hybridisation experiments and thus represent false positive results. In line with this, these cases were always found in tumours showing some other subtype HPV DNA in in situ hybridisation which could be confirmed by PCR (table 2) .
Many samples showed positive amplification on PCR but were negative on in situ hybridisation. This suggests that at least a small copy number of HPV DNA might be more widely present in lung carcinomas than the results of in situ hybridisation suggest. In some cases in situ hybridisation also revealed some faint labelling in neighbouring type II pneumocytes and alveolar macrophages. It It is a widely accepted view that human papilloma viruses localise solely in the nuclei of the infected cells. In our study, however, the HPV positivity was localised in both the nuclear and the cytoplasmic compartments in all cases. This was also observed in our recent in situ hybridisation study of HPV DNA in bronchioloalveolar carcinoma.37 It is possible that our double stranded DNA probes hybridise, not only with viral DNA in nuclei, but also with cytoplasmic mRNA of HPV. This idea is supported by a recent study by Kinoshita et aP°w hich showed the presence of HPV E6-E7 mRNA transcripts in lung carcinoma.
In conclusion, our data show that HPV DNA is present in a high proportion of lung squamous cell and adenocarcinomas. The inverse relationship between HPV infection and abnormal accumulation of p53 protein suggests that p53 is important in lung carcinogenesis and that HPV may contribute to it by binding and inactivating the p53 protein.
This study was supported financially by the Finnish AntiTuberculosis Association, the Finnish Cultural Fund, and the Finnish Cancer Societies. 
